دورية أكاديمية
أعرض في EDS

Mineral trioxide aggregate (MTA) inhibits osteoclastogenesis and osteoclast activation through calcium and aluminum activities.

التفاصيل البيبلوغرافية
العنوان: Mineral trioxide aggregate (MTA) inhibits osteoclastogenesis and osteoclast activation through calcium and aluminum activities.
المؤلفون: Rezende TMB; Programa de Pós-graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brazil. taiambr@gmail.com.; Curso de Odontologia, Universidade Católica de Brasília, Brasília, DF, Brazil. taiambr@gmail.com.; Programa de Pós-graduação em Ciências da Saúde, Universidade de Brasília, Brasília, DF, Brazil. taiambr@gmail.com., Ribeiro Sobrinho AP; Departamento de Odontologia Restauradora, Faculdade de Odontologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil., Vieira LQ; Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil., Sousa MGDC; Programa de Pós-graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brazil., Kawai T; Department of Oral Science and Translational Research, College of Dental Medicine, NOVA Southeastern University, Fort Lauderdale, FL, USA.; Cell Therapy Institute, Center for Collaborative Research, NOVA Southeastern University, Fort Lauderdale, FL, USA.
المصدر: Clinical oral investigations [Clin Oral Investig] 2021 Apr; Vol. 25 (4), pp. 1805-1814. Date of Electronic Publication: 2020 Aug 12.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 9707115 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1436-3771 (Electronic) Linking ISSN: 14326981 NLM ISO Abbreviation: Clin Oral Investig
أسماء مطبوعة: Publication: Berlin : Springer-Verlag
Original Publication: Berlin : Springer, c1997-
مواضيع طبية MeSH: Bone Resorption* , Osteoclasts*, Aluminum/pharmacology ; Aluminum Compounds ; Animals ; Brazil ; Calcium ; Calcium Compounds ; Cell Differentiation ; Drug Combinations ; Mice ; Mice, Inbred BALB C ; Osteogenesis ; Oxides ; RANK Ligand/pharmacology ; Silicates
مستخلص: Objective: To evaluate the effect(s) of mineral trioxide aggregate (MTA) on in vitro RANKL-mediated osteoclast-dependent bone resorption events and the influence of Ca 2+ and Al 3+ on the osteoclastogenesis inhibition by MTA.
Materials and Methods: Two types of osteoclast precursors, RAW 264.7 (RAW) cell line or bone marrow cells (obtained from BALB/c mice and stimulated with recombinant (r) macrophage colony stimulation factor (M-CSF), were stimulated with or without recombinant (r) activator of nuclear kappa B ligand (RANKL), in the presence or absence of MTA for 6 to 8 days. White Angelus MTA and Bios MTA (Angelus, Londrina, Paraná, Brazil) were prepared and inserted into capillary tubes (direct contact surface = 0.50 mm 2 and 0.01 mm 2 ). Influence of MTA on these types of osteoclast precursors was measured by the number of differentiated tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells (RAW and bone marrow cells), TRAP enzyme activity (RAW cells), cathepsin K gene expression (RAW cells), and resorptive pit formation (RAW cells) by mature osteoclasts. Besides, RAW cells were also stimulated with Ca 2+ and Al 3+ to evaluate the influence of these ions on MTA anti-osteoclastogenic potential.
Results: In bone marrow and RAW cells, the number of TRAP-positive mature osteoclast cells induced by rRANKL was significantly inhibited by the presence of MTA compared with control rRANKL stimulation without MTA (p < 0.05), along with the reduction of TRAP enzyme activity (p < 0.05) and the low expression of cathepsin K gene (p < 0.05). In contrast, to control mature osteoclasts, the resorption area on dentin was significantly decreased for mature osteoclasts incubated with MTA (p < 0.05). rRANKL-stimulated RAW cells treated with Ca 2+ and Al 3+ decreased the number of osteoclasts cells. Besides, the aluminum oxide was the dominant suppressor of the osteoclastogenesis process.
Conclusions: MTA significantly suppressed RANKL-mediated osteoclastogenesis and osteoclast activity and, therefore, appears able to suppress bone resorption events in periapical lesions. This process might be related to Ca 2+ and Al 3+ activities.
Clinical Relevance: MTA is an important worldwidely acknowleged biomaterial. The knowledge about its molecular activities on osteoclasts might contribute to improving the understanding of its clinical efficacy.
References: Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55. (PMID: 10080918)
Dent Traumatol. 2008 Feb;24(1):70-3. (PMID: 18173670)
Arch Oral Biol. 1999 Jan;44(1):55-66. (PMID: 10075151)
Calcif Tissue Int. 2006 Oct;79(4):245-54. (PMID: 17033726)
Crit Rev Oral Biol Med. 2001;12(2):125-35. (PMID: 11345523)
Biol Rev Camb Philos Soc. 1993 May;68(2):197-264. (PMID: 8504194)
Biosci Rep. 1989 Dec;9(6):747-51. (PMID: 2692724)
J Endod. 2006 Sep;32(9):897-900. (PMID: 16934638)
J Physiol. 1990 Oct;429:29-45. (PMID: 2277349)
J Biol Chem. 2001 Jan 5;276(1):563-8. (PMID: 11032840)
J Appl Oral Sci. 2003 Dec;11(4):269-82. (PMID: 21394401)
Nature. 2003 May 15;423(6937):337-42. (PMID: 12748652)
J Immunol. 2000 Feb 15;164(4):2102-9. (PMID: 10657664)
J Bone Miner Res. 2001 Aug;16(8):1444-52. (PMID: 11499867)
Biomaterials. 2004 Aug;25(18):4037-45. (PMID: 15046894)
J Bone Miner Res. 1999 May;14(5):669-74. (PMID: 10320514)
Int Endod J. 2005 Dec;38(12):896-903. (PMID: 16343117)
J Endod. 2017 May;43(5):766-773. (PMID: 28292604)
J Dent Res. 2011 Jul;90(7):912-7. (PMID: 21531916)
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Mar;95(3):345-7. (PMID: 12627108)
Infect Immun. 2016 Sep 19;84(10):2802-12. (PMID: 27456834)
Cell. 1998 Apr 17;93(2):165-76. (PMID: 9568710)
Clin Oral Investig. 2019 Mar;23(3):1237-1252. (PMID: 29982967)
Int Endod J. 2005 Sep;38(9):604-9. (PMID: 16104973)
Biochem Biophys Res Commun. 1989 Feb 28;159(1):68-71. (PMID: 2923624)
J Endod. 1993 Dec;19(12):591-5. (PMID: 8151252)
J Oral Rehabil. 2006 Mar;33(3):234-9. (PMID: 16512891)
Braz Dent J. 2015 Jul-Aug;26(4):337-41. (PMID: 26312968)
J Dent Res. 2004 May;83(5):408-13. (PMID: 15111634)
J Appl Oral Sci. 2019 Jan 07;27:e20180150. (PMID: 30624466)
J Bone Miner Res. 2001 Oct;16(10):1747-9. (PMID: 11585336)
Int Endod J. 2006 Oct;39(10):747-54. (PMID: 16948659)
Oral Dis. 2006 May;12(3):283-9. (PMID: 16700737)
J Endod. 2006 Dec;32(12):1194-7. (PMID: 17174682)
J Endod. 2008 Sep;34(9):1066-71. (PMID: 18718367)
J Endod. 2012 Mar;38(3):346-50. (PMID: 22341072)
J Dent. 2007 Aug;35(8):636-42. (PMID: 17566626)
Crit Rev Oral Biol Med. 1998;9(4):498-521. (PMID: 9825224)
Int Endod J. 2007 Aug;40(8):603-11. (PMID: 17627697)
Vaccine. 1997 Aug;15(11):1183-93. (PMID: 9286042)
Biomaterials. 2005 May;26(15):2371-9. (PMID: 15585240)
Science. 1996 Aug 30;273(5279):1236-8. (PMID: 8703060)
Genes Dev. 1999 Sep 15;13(18):2412-24. (PMID: 10500098)
معلومات مُعتمدة: R15 DE027851 United States DE NIDCR NIH HHS
فهرسة مساهمة: Keywords: Aluminum; Calcium; Mineral trioxide aggregate; Osteoclastogenesis; RANKL
المشرفين على المادة: 0 (Aluminum Compounds)
0 (Calcium Compounds)
0 (Drug Combinations)
0 (Oxides)
0 (RANK Ligand)
0 (Silicates)
0 (mineral trioxide aggregate)
CPD4NFA903 (Aluminum)
SY7Q814VUP (Calcium)
تواريخ الأحداث: Date Created: 20200814 Date Completed: 20210318 Latest Revision: 20230712
رمز التحديث: 20230712
مُعرف محوري في PubMed: PMC10335195
DOI: 10.1007/s00784-020-03483-2
PMID: 32789653
قاعدة البيانات: MEDLINE
الوصف
تدمد:1436-3771
DOI:10.1007/s00784-020-03483-2